 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) in a research report report published on Wednesday. The brokerage issued a sell rating on the...

StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Equities research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC Get Free Report) in a note issued to investors on Monday. The brokerage set a sell rating on the biotechnology companys stock. Cyclacel Pharmaceuticals Stock Performance CYCC opened at $0....

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Get Free Report) in a note issued to investors on Sunday. The brokerage set a sell rating on the biotechnology companys stock. Cyclacel Pharmaceuticals Stock ...

In trading on Wednesday, shares of Cyclacel Pharmaceuticals Incs 6% Convertible Exchangeable Preferred Stock (CYCCP) were yielding above the 3.5% mark based on its quarterly dividend (annualized...

Cyclacel Pharmaceuticals' Preferred Stock Crosses Above 3.5% Yield Territory

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC  Free Report)  Analysts at Brookline Capital Management raised their Q3 2023 earnings per share estimates for shares of Cyclacel...

Brookline Capital Management Analysts Raise Earnings Estimates for Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)

Analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC Get Free Report) in a research note issued on Saturday. The brokerage set a sell rating on the biotechnology companys stock. Cyclacel Pharmaceuticals Trading Down 3.5 % NASDAQ CYCC opened at $0.53 on Friday. ...

Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Call Transcript

- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- ...

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals's Earnings Outlook

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Watchers	15,382
52-Wk Low	$0.28
52-Wk High	$1.51

Market Cap	$4.05M
Volume (M)	117.00
52-Wk High	$1.51
52-Wk Low	$0.28

CYCC Cyclacel Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals